BTIG Upgrades United Therapeutics to Buy, Announces $728 Price Target

BTIG analyst Julian Harrison has upgraded United Therapeutics (NASDAQ: UTHR) from a Neutral to a Buy rating. The analyst has set a price target of $728 for the stock.